RT Journal Article
SR Electronic
T1 Adverse Outcomes in Pulmonary Tuberculosis patients on Retreatment Regimen: Evaluation of Pharmacokinetic Estimates as Risk Indicators
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.11.21261879
DO 10.1101/2021.08.11.21261879
A1 Mohan, Anant
A1 Bhatnagar, Anuj
A1 Gupta, Tarang
A1 Kanswal, Sunita
A1 Das, Ujjalkumar
A1 Velpandian, Thirumurthy
A1 Guleria, Randeep
A1 Singh, Urvashi B.
YR 2021
UL http://medrxiv.org/content/early/2021/08/11/2021.08.11.21261879.abstract
AB Patients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated on re-treatment regimen. These patients are known to have adverse outcomes. This study aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcome. Plasma levels of retreatment regimen drugs [Isoniazid(INH), Rifampicin(RIF), Pyrazinamide(PZA), Ethambutol(EMB), and Streptomycin(STM)] were compared between treatment responsive/cured and treatment failure/not-cured patients. Plasma drug levels were analysed by LC-MS/MS at different time points in 134 PTB patients on retreatment regimen. Of the 134 subjects, 108 were cured, 17 patients developed multi-drug resistant TB (MDR-TB), and 9 patients remained smear positive at treatment completion (8 months). The two-hour plasma levels (C2hr) (geometric mean) were lower in ‘Not Cured’ subjects compared to ‘Cured’ subjects Notably, in the 26 ‘Not Cured’ subjects, C2hr plasma levels after first dose at Day0 were significantly low (INH: 0.86 vs 2.94 µg/ml p≤0.002, RIF: 0.56 vs 2.55 µg/ml p≤0.003, PZA: 1.85 vs 26.58 µg/ml p≤0.000 and EMB: 0.72 vs 1.53 µg/ml p≤0.010). In contrast, STM levels were higher (31.84 vs 18.08 µg/ml p ≤0.007). Based on ROC analysis of the data, therapeutic indicator values for successful treatment outcome were C2hr plasma levels of 10.6 µg/ml for PZA, 1.14 µg/ml for RIF, 1.86 µg/ml for INH and 1.24 µg/ml for EMB. Therapeutic failure in PTB patients on retreatment regimen is associated with lower plasma drug levels. Therapeutic drug monitoring would prove useful to maintain drug levels above the minimum cut-off levels for obtaining favourable clinical outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported research grant by the Indian Council of Medical Research, ICMR ,India (year 2012) Grant No. 5/8/5/10/2012-ECD-I. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee, AIIMS, New Delhi ref no. IEC/NP-251/2012 & RP-22/2012All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Raw data is available with the Principal investigator /corresponsding author of the research study.